

FDA approves Linzess to treat constipation in children, teens

June 15 2023, by Lori Solomon



The U.S. Food and Drug Administration approved [Linzess](#) (linaclotide)

as a once-daily treatment for pediatric patients ages 6 to 17 years with functional constipation.

The approval was based on data from 328 participants who were randomly assigned (1:1) to receive Linzess or placebo. A statistically significant benefit and clinically meaningful improvement was seen for 12-week spontaneous bowel movement frequency rate with Linzess compared with placebo, with Linzess-treated patients showing a greater than twofold least squares mean change from baseline in spontaneous bowel movements per week (2.6 versus 1.3). Diarrhea was the most common adverse event reported (4 percent of Linzess-treated patients versus 2 percent of placebo-treated patients).

"Pediatric functional constipation is an all-too-common issue that physicians see every day, yet despite the tremendous distress it causes to our patients and their families, we haven't had an FDA-approved prescription treatment to offer until now," Jeffrey S. Hyams, M.D., from the Connecticut Children's Medical Center and the University of Connecticut in Hartford, said in a statement. "The approval of Linzess for the treatment of [functional constipation](#) in [pediatric patients](#) ages 6 to 17 years old is a meaningful advancement for these [young patients](#)."

Expanded approval of Linzess was granted to Ironwood Pharmaceuticals.

More information: [FDA Approval](#)

Copyright © 2023 [HealthDay](#). All rights reserved.

Citation: FDA approves Linzess to treat constipation in children, teens (2023, June 15) retrieved 2 May 2024 from <https://medicalxpress.com/news/2023-06-fda-linzess-constipation-children-teens.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.